Nanowear

Nanowear is the developer of SimpleSense, a remote diagnostic platform that monitors patients’ metrics such as ECG, heart rate variability, respiratory rate, actigraphy, impedance cardiography, thoracic impedance, and cardio-phonography using non-invasive undergarments equipped with patented nanosensors. The sensors can capture more than 85 biomarkers from human skin, enabling wireless and real-time monitoring that provides medical professionals with analytics reports backed by artificial intelligence (AI).

As of September 2021, SimpleSense has received its third 510(k) clearance and first software-only clearance from the US Food and Drug Administration (FDA). The FDA clearance enables the company to implement standalone AI and deep learning algorithms that will support remote diagnoses.The clearance also enables Nanowear which is focused on monitoring congestive heart failure (CHF) to expand into other clinical areas such as monitoring and diagnosis of hypertension, COPD, sleep apnea, and post-surgical recovery.